PMID: 6986313Jan 1, 1980Paper

Transplantation of fetal pancreatic microfragments via the portal vein to a diabetic patient

Diabetes
C G GrothJ Ostman

Abstract

Human fetal pancreas preserved in culture was used as a donor organ in a 45-yr-old man with diabetes of 14-yr duration complicated by severe retinopathy and nephropathy. Renal failure had been successfully treated by a cadaveric renal transplant 2 yr earlier. Six fetal pancreases, obtained within 30 min of delivery after prostaglandin-induced abortion at 14--20 wk of gestation, were minced and placed in tissue culture for 3 h at the earliest and 15 days at the longest duration. The cultures were harvested 2--3 h before transplantation. Approximately 3 ml of tissue was infused into a right portal vein branch. Azathioprine was continued at 2 mg/kg and prednisolone increased from 10 mg to 100 mg/day on the day of transplantation and gradually reduced to 25 mg/day. Only two doses of antilymphocytic globulin were given because of a severe reaction. During the 40 days since transplantation, insulin requirements have not changed, but C-peptide has appeared in the urine, suggesting function of the transplanted tissue.

Citations

Jul 1, 1984·Diabetologia·A AnderssonA Schnell
May 1, 1992·Transplant International : Official Journal of the European Society for Organ Transplantation·L C Koo Seen LinI McColl
Jan 1, 1981·The Journal of Clinical Investigation·G K KyriakidesJ Miller
Dec 1, 1993·The Anatomical Record·M M el-NaggarM Tahir
Jun 1, 1989·The Journal of Surgical Research·D K LeonardD A Hullett
Apr 1, 1989·The Journal of Diabetic Complications·L Jovanovic-PetersonC M Peterson
Jan 1, 1989·The Journal of Diabetic Complications·C M PetersonK Williams
May 24, 2001·Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Für Toxikologische Pathologie·A GaumannJ Schrezenmeir
Jan 1, 1981·Upsala Journal of Medical Sciences·B PeterssonJ Ostman
Mar 1, 1994·Cell Transplantation·A Fine

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

American Diabetes Association Journals

Discover the latest diabetes research published by the journals from the American Diabetes Association.